Rehman Mubashar, Ihsan Ayesha, Madni Asadullah, Bajwa Sadia Zafar, Shi Di, Webster Thomas J, Khan Waheed S
Department of Pharmacy, The Islamia University of Bahawalpur, Bahawalpur, Punjab, Pakistan.
Nanobiotech Group, National Institute of Biotechnology and Genetic Engineering, Faisalabad, Punjab, Pakistan.
Int J Nanomedicine. 2017 Nov 21;12:8325-8336. doi: 10.2147/IJN.S147506. eCollection 2017.
Thermoresponsive drug delivery systems are designed for the controlled and targeted release of therapeutic payload. These systems exploit hyperthermic temperatures (>39°C), which may be applied by some external means or due to an encountered symptom in inflammatory diseases such as cancer and arthritis. The objective of this paper was to provide some solid evidence in support of the hypothesis that solid lipid nanoparticles (SLNs) can be used for thermoresponsive targeting by undergoing solid-liquid phase transition at their melting point (MP). Thermoresponsive lipid mixtures were prepared by mixing solid and liquid natural fatty acids, and their MP was measured by differential scanning calorimetry (DSC). SLNs (MP 39°C) containing 5-fluorouracil (5-FU) were synthesized by hot melt encapsulation method, and were found to have spherical shape (transmission electron microscopy studies), desirable size (<200 nm), and enhanced physicochemical stability (Fourier transform infrared spectroscopy analysis). We observed a sustained release pattern (22%-34%) at 37°C (5 hours). On the other hand, >90% drug was released at 39°C after 5 hours, suggesting that the SLNs show thermoresponsive drug release, thus confirming our hypothesis. Drug release from SLNs at 39°C was similar to oleic acid and linoleic acid nanoemulsions used in this study, which further confirmed that thermoresponsive drug release is due to solid-liquid phase transition. Next, a differential pulse voltammetry-based electrochemical chemical detection method was developed for quick and real-time analysis of 5-FU release, which also confirmed thermoresponsive drug release behavior of SLNs. Blank SLNs were found to be biocompatible with human gingival fibroblast cells, although 5-FU-loaded SLNs showed some cytotoxicity after 24 hours. 5-FU-loaded SLNs showed thermoresponsive cytotoxicity to breast cancer cells (MDA-MB-231) as cytotoxicity was higher at 39°C (cell viability 72%-78%) compared to 37°C (cell viability >90%) within 1 hour. In conclusion, this study presents SLNs as a safe, simple, and effective platform for thermoresponsive targeting.
热响应性药物递送系统旨在实现治疗药物的可控和靶向释放。这些系统利用高温(>39°C),这种高温可通过某些外部手段施加,或者由于在诸如癌症和关节炎等炎症性疾病中出现的症状而产生。本文的目的是提供一些确凿证据,以支持以下假设:固体脂质纳米粒(SLNs)可通过在其熔点(MP)发生固-液相转变用于热响应性靶向。通过混合固体和液体天然脂肪酸制备热响应性脂质混合物,并通过差示扫描量热法(DSC)测量其熔点。采用热熔包封法合成了含有5-氟尿嘧啶(5-FU)的SLNs(MP 39°C),发现其呈球形(透射电子显微镜研究)、尺寸理想(<200 nm)且具有增强的物理化学稳定性(傅里叶变换红外光谱分析)。我们观察到在37°C(5小时)时呈现持续释放模式(22%-34%)。另一方面,5小时后在39°C时>90%的药物被释放,这表明SLNs呈现热响应性药物释放,从而证实了我们的假设。在39°C时SLNs的药物释放与本研究中使用的油酸和亚油酸纳米乳剂相似,这进一步证实了热响应性药物释放是由于固-液相转变。接下来,开发了一种基于差分脉冲伏安法的电化学化学检测方法,用于快速实时分析5-FU的释放,这也证实了SLNs的热响应性药物释放行为。发现空白SLNs与人牙龈成纤维细胞具有生物相容性,尽管负载5-FU的SLNs在24小时后表现出一定的细胞毒性。负载5-FU的SLNs对乳腺癌细胞(MDA-MB-231)表现出热响应性细胞毒性,因为在1小时内,与37°C(细胞活力>90%)相比,在39°C时细胞毒性更高(细胞活力72%-78%)。总之,本研究表明SLNs是一种用于热响应性靶向的安全、简单且有效的平台。